Skip to main content

Inpharmatica Picks up ADME-related IP, Lab Space, Research Staff from ArQule

NEW YORK, June 23 - Inpharmatica said today that it plans to acquire certain assets relating to ADME (absorption, distribution, metabolism, and excretion) research from ArQule.


Specifically, Inpharmatica will take over ArQule's 10,000-square-foot Cambridge, UK, laboratories and will license some of the company's intellectual property. Fifteen of ArQule's Cambridge-based research staff will join Inpharmatica following the deal, which is subject to certain third party consents and agreements.


Financial terms of the acquisition were not disclosed.


Inpharmatica said it plans to use the newly acquired technology to enhance its PharmaCarta chemogenomics technology platform and to advance its internal discovery programs to the pre-clinical phase.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.